Wet age-related macular degeneration
|
|
0.010 |
GeneticVariation
|
BEFREE |
The purpose of this study is to evaluate the effect of complement factor H (CFH) Y402H CC and TT polymorphisms on treatment response to intravitreal ranibizumab injection in patients with wet age-related macular degeneration (AMD).
|
24367156 |
2013 |
Venous Thromboembolism
|
|
0.010 |
GeneticVariation
|
BEFREE |
In contrast to expected results, we found no association of Y402H polymorphism with risk of atherothrombosis (adjusted: myocardial infarction, OR=1.09, 95%CI 0.88-1.36, p=0.43; ischaemic stroke, OR=1.11, 95%CI 0.81-1.54, p=0.52; venous thromboembolism, OR=1.41, 95%CI 0.88-2.24, p=0.15), nor with baseline plasma C-reactive protein levels [median (interquartile range) mg/L: YY, 1.39 (0.70-2.60); YH, 1.10 (0.57-2.16); HH, 1.00 (0.48-1.79); p=0.14].
|
16229850 |
2006 |
Vascular Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
We, therefore, evaluated the CFH genetic variant Y402H amongst 685 Caucasian individuals who subsequently developed arterial or venous thrombotic event (incident myocardial infarction (MI), ischaemic stroke, or venous thromboembolism) and amongst 685 age- and smoking-matched Caucasian individuals who remained free of reported vascular disease during follow-up (controls) within the Physicians' Health Study cohort.
|
16229850 |
2006 |
Uveitis, Posterior
|
|
0.010 |
GeneticVariation
|
BEFREE |
Carriage of the CFH Y402H polymorphism in both alleles is associated with an increased risk for posterior uveitis and panuveitis presentation.
|
23497844 |
2013 |
Thrombotic Microangiopathies
|
|
0.010 |
GeneticVariation
|
BEFREE |
Subsequent tests revealed elevated serum levels of soluble C5b-9, and genetic testing revealed compound heterozygous c.184G > A (Val62Ile) and c.1204T > C (Tyr402His) single-nucleotide polymorphisms in complement factor H.We encountered a case of complement-mediated TMA accompanied by DIC, which was successfully treated with eculizumab.
|
28178155 |
2017 |
Systemic Inflammatory Response Syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
Homozygosity for the complement factor H Y402H polymorphism, which is thought to reduce complement inhibition, was associated with less frequent SIRS/sepsis (the adjusted odds ratio for the homozygous variant complement factor H Y402H [CC] carriers was 0.3, 95% confidence interval, 0.1-0.7, p = .005).
|
20351616 |
2010 |
Sudden sensorineural hearing loss
|
|
0.010 |
GeneticVariation
|
BEFREE |
We conclude that CFH Y402H polymorphism and SSNHL risk are significantly related, and that diabetic CFH Y402H minor allele carriers may be susceptible to SSNHL.
|
22426290 |
2012 |
Stargardt's disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
CFH Y402H polymorphism in Italian patients with age-related macular degeneration, retinitis pigmentosa, and Stargardt disease.
|
30285522 |
2018 |
Soft drusen
|
|
0.040 |
GeneticVariation
|
BEFREE |
After adjusting for age and other covariants, the CFH CC (Y402H polymorphism) genotype was associated with an increased likelihood of bilateral compared with unilateral involvement by any soft drusen (odds ratio [OR], 2.5; 95% confidence interval [CI], 1.4-4.5), distinct soft drusen (OR, 2.8; 95% CI, 1.0-8.1), and pigmentary abnormalities (OR, 1.7; 95% CI, 1.0-2.8).
|
19822851 |
2009 |
Soft drusen
|
|
0.040 |
GeneticVariation
|
BEFREE |
Also in the Chinese population, soft drusen as part of age-related maculopathy are associated with the Y402H polymorphism in the complement factor H gene despite a markedly lower frequency of C allele in the Chinese population than in white populations.
|
20038862 |
2010 |
Soft drusen
|
|
0.040 |
GeneticVariation
|
BEFREE |
Furthermore, we show that the Y402H variant confers similar risk of soft drusen and both forms of advanced AMD (GA or neovascular AMD).
|
16300415 |
2006 |
Soft drusen
|
|
0.040 |
GeneticVariation
|
BEFREE |
CFH Y402H is associated with disease progression, with soft drusen and hyperpigmentation as high-risk features.
|
29453225 |
2018 |
Septicemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
Homozygosity for the complement factor H Y402H polymorphism, which is thought to reduce complement inhibition, was associated with less frequent SIRS/sepsis (the adjusted odds ratio for the homozygous variant complement factor H Y402H [CC] carriers was 0.3, 95% confidence interval, 0.1-0.7, p = .005).
|
20351616 |
2010 |
Septicemia
|
|
0.020 |
GeneticVariation
|
BEFREE |
A case-control method (488 septic patients and 527 healthy individuals) was carried out in this study to investigate the genetic relationship between CFH polymorphisms (rs3753394 C/T, rs1065489 G/T and rs1061170 C/T) and susceptibility to sepsis caused by bacterial infections in Chinese Han populations.
|
31525397 |
2020 |
Sepsis
|
|
0.020 |
GeneticVariation
|
BEFREE |
A case-control method (488 septic patients and 527 healthy individuals) was carried out in this study to investigate the genetic relationship between CFH polymorphisms (rs3753394 C/T, rs1065489 G/T and rs1061170 C/T) and susceptibility to sepsis caused by bacterial infections in Chinese Han populations.
|
31525397 |
2020 |
Sepsis
|
|
0.020 |
GeneticVariation
|
BEFREE |
Homozygosity for the complement factor H Y402H polymorphism, which is thought to reduce complement inhibition, was associated with less frequent SIRS/sepsis (the adjusted odds ratio for the homozygous variant complement factor H Y402H [CC] carriers was 0.3, 95% confidence interval, 0.1-0.7, p = .005).
|
20351616 |
2010 |
Schizophrenia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Next, we performed a genotype-phenotype analysis to identify the relationship between <i>CFH</i> Y402H polymorphism and clinical features of schizophrenia.
|
28293111 |
2017 |
Rheumatoid Arthritis
|
|
0.010 |
GeneticVariation
|
BEFREE |
The CFH variants, I62V, Y402H, IVS1 and IVS10, known to associate strongly with AMD, did not show a significant association with the risk of developing RA despite a strong statistical power to detect such differences.
|
22059990 |
2011 |
Retinal Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
The Y402H variant of complement factor H is associated with age-related macular degeneration but not with diabetic retinal disease in the Go-DARTS study.
|
19646183 |
2009 |
Retinal angiomatous proliferation
|
|
0.020 |
GeneticVariation
|
BEFREE |
Y402H was associated with tAMD (P = 3.00 × 10(-5)) and with PCV (P = 9.73 × 10(-5)), but no association was found with RAP, possibly because of the small sample size and the rare minor allele.
|
20574013 |
2010 |
Retinal angiomatous proliferation
|
|
0.020 |
GeneticVariation
|
BEFREE |
Pooled overall odds ratios for RAP/AMD were 1.15 (95% CI 0.60-2.18) for GT versus GG, 3.52 (95% CI 1.25-9.91) for TT versus GG ARMS2, 0.98 (95% CI 0.22-4.29) for GA versus AA, 1.00 (95% CI 0.25-4.02) for GG versus AA CFHI62V, 0.57 (95% CI 0.35-0.93) for CT versus TT CFH Y402H, and 0.40 (95% CI 0.22-0.74) for CC versus TT CFH Y402H.
|
28005184 |
2017 |
Reticular pseudodrusen
|
|
0.040 |
GeneticVariation
|
BEFREE |
Comparison of above-mentioned ORs revealed statistically higher values for GT and TT genotypes of ARMS2 A69S compared with CFH Y402H genotypes (p = 0.011, p = 0.014, respectively).Our analysis showed stronger contribution of ARMS2 in AMD with RPD group versus AMD without RPD group, in comparison with CFH genotypes.
|
28593728 |
2018 |
Reticular pseudodrusen
|
|
0.040 |
GeneticVariation
|
BEFREE |
The ARMS2 single nucleotide polymorphism (SNP) rs10490924, HTRA1 SNPs rs11200638 and rs3793917, and CFH SNPs rs393955, rs1061170, and rs2274700 were associated with increased prevalence of RPD (all P < 0.05).
|
26681391 |
2016 |
Reticular pseudodrusen
|
|
0.040 |
GeneticVariation
|
BEFREE |
Six single nucleotide polymorphisms-rs10490924 (ARMS2), rs1061170 (CFH), rs2230199 (C3), rs116503776 and rs114254831 (C2/CFB), and rs943080 (VEGF-A)-and the genetic risk score (GRS) were assessed for association with RPD.
|
31558345 |
2019 |
Reticular pseudodrusen
|
|
0.040 |
GeneticVariation
|
BEFREE |
CFH Y402H, ARMS2, HTRA1, and C3 were significantly associated with reticular pseudodrusen.
|
29801032 |
2018 |